Kornimate/medical-research-clean huggingface dataset:
personalized upper extremity rehabilitation for persons with stroke

Conditions: Stroke

Summary: approximately 80% of individuals with chronic stroke present with long lasting upper extremity (ue) impairments. advances in rehabilitation technology, such as robotics, virtual reality (vr) and neuromuscular electrical stimulation (nmes), have separately demonstrated their effectiveness in improving ue function of individuals with stroke. the potential to influence recovery may be further enhanced by combining these modalities in order to target motor deficits of the individual. research has shown that not all persons with stroke may be able to recover hand function. in particular, such recovery depends on the integrity of the corticospinal tract (cst), which links the motor areas of the brain to the ue (and hand) musculature. instead of using a 'one-size-fits-all' approach to ue rehabilitation, cst integrity will be assessed through transcranial magnetic stimulation (tms), a non-invasive approach, and match the intervention to the individual's specific impairments. the personalized upper extremity rehabilitation (super) intervention is proposed, which combines robotics, vr activities, and nmes. the objectives of this study are to determine the feasibility of the super intervention in individuals with moderate/severe stroke. stroke participants will receive a 5-week intervention (3x per week) combining robotic therapy and vr activities, based on their functional level. those with low potential for hand recovery will receive an intervention focussing on elbow and shoulder movements. for those with a good potential for hand recovery, the last 30 minutes of the robotic or vr session will be complemented by muscle-triggered nmes. feasibility indicators associated with process, resources, management and treatment will be measured. outcomes of ue and hand function will include the fugl-meyer upper extremity assessment, the box and block test and the abilhand. it is expected that feasibility criteria will be met and that the super intervention will lead to significant improvements in ue impairment compared to a waitlist group.


Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic stroke * moderate to severe ue impairment (score between 2 and 4 out of 7 on the chedoke-mcmaster each of the arm and hand components * at least 3 months post stroke * no longer receiving rehabilitation services. exclusion criteria: * medical instability * marked cognitive deficits (minicog score 2 or lower) * uncorrected visual impairments * shoulder pain that would limit participation in the study * severe spasticity at the affected ue
evaluation of the safety and efficacy of azvudine and paxlovid in the treatment of hospitalized patients with covid-19

Conditions: Paxlovid; Azvudine; COVID-19

Summary: in this retrospective study, we aimed to evaluate the clinical efficacy and safety of two antiviral drugs on covid-19 and inpatients with existing complications in the first affiliated hospital of shandong first medical university. in addition, we also explored a key issue. is the combined treatment effect of two antiviral drugs, paxlovid and azvudine, better than the use of a single drug?

we conducted a single center retrospective cohort study on hospitalized patients with severe acute respiratory syndrome coronavirus type 2 infection who received treatment with nimatevir/ritonavir tablets or azivudine tablets at the first affiliated hospital of shandong first medical university from december 1，2022 to january 31，2023. in the research of this project, it is necessary to extract, sort out and retrospectively analyze the clinical data of all patients with covid-19 who have received nematovir/ritonavir tablets or azivudine tablets in the first affiliated hospital of shandong first medical university (shandong qianfoshan hospital), and respectively identify the relevant epidemiological characteristics of covid-19 patients, it is planned to use multiple linear regression or logical regression model to explore the relevant factors that affect the drug use efficiency index, safety index and total cost of patients with covid-19, so as to provide scientific and quantitative evidence support for the drug use mode of the disease, the clinical value of the drug and the rational drug use of patients, and also provide favorable basis for the supervision and decision-making of smart pharmacy of medical institutions.

Eligibility criteria:
inclusion criteria: * 1. the patient's admission time is from december 1,2022 to january 31,2023. 2. the patient has used either paxlovid or azivudine tablets during admission. 3. age ≥ 18 years old. exclusion criteria： * 1. patients using other antiviral drugs. 2. patients with incomplete clinical data.

Keywords: paxlovid azvudine covid-19 effectiveness real-world evidence
advanced gastrointestinal endoscopic imaging

Conditions: Gastrointestinal Diseases; Gastric (Stomach) Cancer; Gastrointestinal Stromal Tumor (GIST)

Summary: to develop new methods to detect malignant and premalignant conditions of the gastrointestinal tract.


Eligibility criteria:
inclusion criteria:patients be at least 18 years of age, either genders all ethnic backgrounds will be considered. patients who are scheduled for endoscopy by one of the investigators will be asked if they are interested in participating in the study. the study will be open to all patients undergoing endoscopy that do not have exclusion criteria. we will ask all patients if they are participating in any other studies. if they are participating in any other study then we will ask them for more information to determine whether there could be any harm from participating in both studies and if there is then they will not be enrolled. exclusion criteria:patients with unstable vital signs will not be included.
cervical range of motion in neck pain patients: a mixed methods study

Conditions: Neck Pain

Summary: this study there are any associations between objective and subjective outcome measures, measuring the cervical range of motion and if the restriction matter to the patient.

objective and subjective outcome measures are frequently used assessments in clinical practice. the investigators will use different subjective and objective outcome measures to evaluate any possible associations, as well as to investigate if restrictions of movement matters to patients. additionally to the assessments tools the investigators will use interviews to extend the scope.

Eligibility criteria:
inclusion criteria: * patients with any duration of neck pain * men and women older than 18 years * signed informed consent exclusion criteria: * disc herniation of the cervical spine * spinal canal stenosis * acute accidents * surgery of the cervical spine * pacemaker and / or defibrillator
dysport for the treatment of omd

Conditions: Oral Dystonia; Tardive Dystonia

Summary: the purpose of this study is to study the efficacy and safety of abobotulinumtoxina (dysport) for use in oromandibular dystonia (omd).

oromandibular dystonia (omd) is an uncommon, disabling form of cranial dystonia, involving involuntary movements of the lower facial, masticatory, and lingual muscles. this can cause jaw movements including opening, closure, protrusion, retraction, or deviation. common additional facial movements involve grimacing or lip pursing. when there is tongue involvement, it usually presents as tongue protrusion or curling. such patients are impaired in relation to eating, speaking and swallowing this study aims to evaluate the efficacy and safety of a low dose of dysport® deemed tolerable during phase 1 in subjects with oromandibular dystonia (omd). participants will be injected with dysport® only, with an unblinded open-label disclosure. the safety and efficacy pf receiving dysport® will be recorded for all subjects that undergo injection. all subjects will be examined and videotaped at the injection visit, then at 6 and 12 weeks after injection with a standardized protocol. the primary outcome will be blinded examination scores of the videos performed after the study is complete.the evaluators will be three different movement disorders experts, not otherwise involved in the study, who will review the videotaped examinations, presented in a random order, using the global dystonia rating scale (gds). evaluators will rate the dystonia at baseline (injection visit) and 6 weeks after injection.

Eligibility criteria:
inclusion criteria: * a diagnosis of primary or tardive omd * moderate or severe severity, defined as gds score ≥4 in either "lower face" or "jaw and tongue" section * capability of attending the scheduled visits * only those who have been previously injected with onabotulinumtoxina and responded to that treatment, and are at least 12 weeks post last injection * women of childbearing age need to use contraception in order to be included. exclusion criteria: * existence of a systemic disease that could confound the evaluation * previous placement of deep brain stimulation electrodes to treat dystonia * concomitant oral medications that could interfere with the action of botulinum toxin type a (e.g., aminoglycosides) * on an unstable dosage of any medication prescribed to treat dystonia (e.g., benzodiazepines, baclofen or anticholinergics) * any known hypersensitivity to any botulinum toxin preparation and allergy to cow's milk protein * immunoresistance to other forms of botulinum toxin type a * existence of a concomitant neuromuscular disorder (e.g., myasthenia gravis or lambert-eaton syndrome, etc) * infection at the proposed injection sites * pregnant women * women of childbearing age not on contraception * breastfeeding women * inability to comply with scheduled visits * patients who had been previously injected with botulinum toxin type a but who did not respond

Keywords: oromandibular dystonia oral dystonia tardive dystonia botulinum toxin abobotulinumtoxina
quantification of clinically relevant drug induced changes in hbo2 affinity

Conditions: Oxygen Deficiency

Summary: the presented study is an experimental in-vitro study without intervention in-vivo. the effects of nitric oxide and prostacyclins, 5-hydroxymethylfurfural and alpha-ketoglutarate, volatile anaesthetics on haemoglobin oxygen (hbo2) affinity will be investigated in-vitro. venous blood samples of 20 healthy young volunteers (10 female, 10 male) will be collected twice in the period of one week. informed consent will be given. every blood collection will be accompanied by a venous blood gas analysis. the blood samples will be transferred to the laboratory for in-vitro recording of the complete oxygen dissociation curve (odc). a newly developed in-vitro method will be used. on the first study day the blood samples will be exposed to three different concentrations of nitric oxide during the measurement, followed by two different vapourized prostacyclins. in addition, different concentrations of 5-hydroxymethylfurfural and alpha-ketoglutarate will be given to the blood samples for odc recording. on the second study day the dose dependent effects of three different volatile anaesthetics will be investigated by exposing the blood samples to these drug while the measurements. following these odc recordings, aliquots of the blood samples will be frozen and investigated for storage related changes in hbo2 affinity.


Eligibility criteria:
inclusion criteria: * informed consent * asa 1 (american society of anesthesiologists classification) exclusion criteria: * any drug intake within 10 days prior to blood collection * smoking * haemoglobinopathy * acute inflammatory disease within 14 days prior to blood collection * pregnancy or breastfeeding * severe trauma or blood loss within 14 days prior to blood collection * participation in any other clinical study * high altitude sojourn for several days (\> 3,000 m) within four weeks prior to blood collection
orthopaedic treatment proximal humeral fractures

Conditions: Proximal Humeral Fracture

Summary: prospective non-randomized, open, unicentric observational study to compare two different treatments for three-four parts fractures of proximal humerus (neer's classification) in elderly patients (over 75 years old). both technics are: sling inmobilization and shoulder arthroplasty.

the investigators propose an observational study that aims to assess: * primarily, the functional results of a cohort of 20 pacients presenting fractures of 3 and 4 parts of proximal humerus (according to (neer's classification) that will be treated orthopedically (this is, non-surgically). this patients will be recruited in the emergency room of our center, and after being diagnosed of their fracture, will be treated with a sling for three weeks and subsequent rehabilitation treatment. our intention is to assess the function of the injured shoulder using functional scales (ases, dash and constant score, and vas scale) at the time of three and twelve months from the date of the trauma. * secondly the investigators want to compare the results obtained in this cohort with the results of a historical cohort of patients operated in our center with the same type of fracture. both types of treatment (non-surgical and shoulder prosthesis) are valid for this type of fracture, and endorsed by the scientific literature. the investigators consider this to be an observational study since it assigns a single cohort of patients a single treatment (ie non-surgical treatment). the conservative treatment for this fractures is part of routine medical care, and the object of this study is to evaluate the effect of this intervention.

Eligibility criteria:
inclusion criteria: * 75 years or older. * 3 or 4 parts fracture (neer's classification). exclusion criteria: * comorbilities affecting to functional recovery. * fractures associating shoulder dislocation. * open fractures including neurovascular damage. * polytraumatized patients
the relation between oral hygiene and microbial load in the oral cavity after restoring primary molars with two types of ready-made crowns

Conditions: Carious Lesion; Ready-made Crowns

Summary: following the restoration of primary molars with stainless steel and bioflex crowns, an evaluation of the current state of oral hygiene in relation to the amount of microorganisms and gingival health in the oral cavity will be carried out.


Eligibility criteria:
inclusion criteria: * participants aged between 4 and 8 years. * pulp therapy treated primary molars on the contralateral side, requiring a full coverage restoration (split-mouth technique). * no history of any antibiotic consumption 2 weeks before the procedure. * no history of fluoride application 2 weeks before the procedure. exclusion criteria: * special children with physical disabilities or emotional disturbances. * children are diagnosed with systemic diseases. * grossly destructed teeth with non-restorable crown structure. * primary teeth with shedding or pathological tooth mobility.

Keywords: primary crowns, oral health
a study of tas0612 in participants with advanced or metastatic solid tumor cancer

Conditions: Advanced or Metastatic Solid Tumors

Summary: the purpose of this study is to see if tas0612 is safe in participants with advanced or metastatic solid tumor cancer.


Eligibility criteria:
inclusion criteria: dose escalation: have histologically confirmed, locally advanced, and unresectable cancer, or metastatic cancer and have progressed on or were intolerant to standard treatments or refused standard of care (soc). dose expansion: have documented histologically or cytologically confirmed adenocarcinoma of the prostate with documented pten loss or loss of function mutation, who have metastatic castration-resistant disease and have: * disease progression per the prostate cancer clinical trials working group 3 (pcwg3)/modified recist 1.1 after the most recent regimen. * received androgen receptor directed therapy previously with or without chemotherapy consisting of no more than 2 prior taxane-based regimens. * been receiving androgen deprivation therapy with serum testosterone \<50 ng/dl (\<2.0 nm). note: previously documented pten loss or loss of function mutation from archived tissue sample testing or cfdna sample testing is acceptable if done in a clia certified lab or a locally certified lab. have an ecog score of 0 or 1 dose escalation (part 1): have no measurable or measurable disease per response evaluation criteria in solid tumors (recist) 1.1. dose expansion (part 2): have measurable or no measurable disease per pcwg3/modified recist 1.1 • no more than 30 patients with no measurable disease will be enrolled in dose expansion (part 2). exclusion criteria: * participating in medical research not compatible with this study * have not discontinued or recovered from previous treatments for cancer * have a significant cardiac condition * have untreated brain metastases * have a primary brain tumor * have a serious concomitant disorder * unable to swallow or digest pills * poorly controlled diabetes * concomitant medications or substances that are strong inhibitors/inducers of cyp3a.study

Keywords: solid tumors akt inhibitor rsk inhibitor s6k inhibitor kinase inhibitor phase i prostate cancer pten loss pten mutation
growth hormone secretion following the anaerobic exercise

Conditions: Short Stature; Obesity, Childhood

Summary: proper growth in children is a complex process regulated by a combination of genetic, nutritional, environmental, hormonal, and others. growth hormone (gh) is the main hormone regulating the growth from childhood to adulthood. despite great progress in the field, with the development of recombinant gh for the treatment of growth hormone deficiency (ghd), there is still no reliable method for testing ghd. physical exertion is one of the significant physiologic stimuli for gh secretion, and it is reliable test for identification of ghd. it is not in use in the clinics because of its complexity. recently gh secretion following short anaerobic exercise in young adults was tested and also demonstrated significant growth hormone secretion in contrast to adult children's exercise is characterized by an anaerobic nature. there is no data about secretion of growth hormone in response to anaerobic exercise in children. purpose of the experiment: the purpose of this study is to evaluate the secretion of growth hormone in response to anaerobic exercise in children.

100 children aged 6-16 years, followed at the pediatric endocrinology clinic for growth assessment or obesity. assessment of their growth hormone axis will be evaluate in parallel according to the currently accepted pharmacological gh testing as accepted and also following anaerobic physical test. after explanation to the patient and his parent and obtaining an informed consent, the children will be instructed to pedal at maximum speed for 15 seconds x 10 sprints (1 minute of recovery between the sprints) against a resistance adjusted according to their body mass index. the test will perform in similarity to gh provocative protocols by mean that they will be performed in the morning after a night's sleep and overnight fasting. the patients will be remained fasting during the test. they will be asked not to exercise a day before the test. thirty minutes before the test, venflon will be inserted and the child will receive an explanation and rest until the beginning of the test. blood gh, igf-1, cortisol will be taken at the beginning of exercise (time 0), at the end of exercise, after 30 minutes, 45 minutes and 60 minutes is customary according to criteria set pharmacological inventory growth hormone. the test results will be compared to pharmacological testing of the child if available.

Eligibility criteria:
inclusion criteria: * children evaluated for short stature * normal weight \\ overweight \\ obesity exclusion criteria: * known gh deficiency
the effect of providing stratification of low risk penicillin allergies on penicillin allergy label removal

Conditions: Penicillin Allergy

Summary: currently it is estimated that at least 25 million people in the united states are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin allergy labels means these services are available only through specialty allergy practices. there is therefore a need to provide evidence for alternative penicillin de-labeling strategies such as direct oral challenge. previous studies have utilized quasi-experimental designs. test dose challenges are currently recommended as a strategy for removal of low risk drug allergies, but the current experience is limited to single arm observational studies and evidence-based strategies for identifying low risk patients are lacking. our objective is to demonstrate the benefit of providing risk stratification in removing penicillin allergy labels for low risk penicillin allergy patients in a randomized controlled trial.


Eligibility criteria:
inclusion criteria: * vumc patients age 18 or older with a penicillin allergy reported in their chart, and are medically stable, currently admitted to stepdown unit or regular floor bed. exclusion criteria: * patients with a penicillin allergy reported in their chart, but who are currently medically unstable. * pregnant patients
a retrospective chart review study of patients with chronic lung allograft dysfunction-bronchiolitis obliterans syndrome (clad-bos) post lung transplantation

Conditions: Bronchiolitis Obliterans Syndrome Due to and After Lung Transplantation (Disorder)

Summary: the aim of this study is to describe the forced expiratory volume in 1 second (fev1) decline and natural disease evolution in patients affected by clad-bos after lung transplantation and receiving an immunosuppressive therapy as standard of care.

this is a retrospective, multinational, multicenter chart review study of adult patients with clinically diagnosed clad-bos after lung transplantation. all data will be retrospectively collected from patient records starting from lung transplantation date through last date of available data, and as such, no interventions will be applied as part of this study. the observational period for each patient will be from lung transplant date until last date of data available or death, whichever occurs earlier and will include the following time periods: diagnosis window: 01 january 2013 through most recent data available.

Eligibility criteria:
inclusion criteria: 1. adult patients ≥ 18 years of age on the date of clad-bos diagnosis 2. patients with a clad-bos clinician diagnosis from as early as 01 january 2013 3. patients with clad-bos clinician diagnosis made at least 12 months after lung transplant 4. patients received at least basic maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to mycophenolate mofetil or azathioprine (or other anti-proliferative agent), and a systemic corticosteroid such as prednisone as third agent for at least 1 month before the index date. as long as the basic maintenance regimen is maintained for the abovementioned period, patients will still be considered eligible for the study even if they are receiving other immunosuppressive agents in addition to the basic maintenance regimen. exclusion criteria: 1. patients with severe concomitant disease at the time of index date, which according to physician's judgment, can interfere with clad-bos progression and mortality (e.g., malignancies, severe chronic diseases) 2. patients who have been exposed to any investigational medical products in the 4 weeks prior to index date or during the post-diagnosis period 3. patients with confirmed other clad phenotype (e.g., restrictive allograft syndrome) according to physician's judgment.